Acceleron Pharma to Participate in Four Healthcare Investor Conferences in March

CAMBRIDGE, Mass.--()--Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic candidates that regulate cellular growth and repair, today announced that senior management will participate in four upcoming healthcare investor conferences in March.

Conference Details:

Event:   Cowen and Company 36th Annual Health Care Conference
Date / Time: Wednesday, March 9, 2016 at 10:40 AM EST
Location: Boston Marriot Copley Place, Boston, MA
 
Event: LEERINK Partners Annual Emerging Biotech Conference
Date / Time: Wednesday, March 9, 2016 at 7:00 AM MST
Location: The Cliff Lodge, Snowbird, UT
 
Event: Barclays Global Healthcare Conference
Date / Time: Thursday, March 17, 2016 at 11:15 AM EDT
Location: Loews Miami Beach Hotel, Miami Beach, FL
 
Event: Morgan Stanley Healthcare Corporate Access Day
Date / Time: Wednesday, March 23, 2016
Location: Four Seasons Hotel Boston, Boston, MA
 

Live audio webcasts for the Cowen and Company and Barclays Global Healthcare conferences will be available on the “Events and Presentations” page in the Investors & Media section on the Company’s website (www.acceleronpharma.com). A replay of the webcasts will also be available from Acceleron’s website.

About Acceleron

Acceleron is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic candidates that regulate cellular growth and repair. The company is a leader in understanding the biology of the Transforming Growth Factor-Beta protein superfamily, a large and diverse group of molecules that are key regulators in the growth and repair of tissues throughout the human body, and in targeting these pathways to develop important new medicines. Acceleron has built a highly productive R&D platform that has generated innovative clinical and preclinical therapeutic candidates with novel mechanisms of action. These therapeutic candidates have the potential to significantly improve clinical outcomes for patients with cancer and rare diseases.

For more information, please visit www.acceleronpharma.com. Follow Acceleron on Social Media: @AcceleronPharma and LinkedIn.

Contacts

Acceleron Pharma Inc.
Todd James, 617-649-9393
Senior Director, Investor Relations and Corporate Communications
or
Media:
BMC Communications LLC
Brad Miles, 646-513-3125

Recent Stories

RSS feed for Acceleron Pharma

Acceleron Pharma